1. Scrip
  2. >>Drug Pricing

Data, Data, Everywhere, But How Much Of It Makes A Real Difference?

Philips Makes A Case For The Value Approach

 
• By Ashley Yeo

Having a single patient's complete health care information all in one place was a dream that US visionaries began to talk up around a decade ago. The idea was that fast, electronic support for doctors would aid clinical decision making and efficiency. Ten years on, there is still much work to do before the dream is realized, says Philips' Carla Kriwet. But a solution is within reach.

hand touching screen with medical data
• Source: Shutterstock

Doctors ostensibly have a single, clear task – easy to describe maybe, but usually anything but to deliver. And the two questions they need answers to have never changed: what is the next best thing to do for the patient and what are the risks associated with that course of action? This is what they require, yet the device technologies and data intelligence offerings available are still not delivering the targeted answers they need for the patient sat before them.

Carla Kriwet, CEO of Connected Care and Health Informatics for Philips Healthcare, told In Vivo that in spite of the volumes of data available to health care professionals, too...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.